CTLA4 and prostate cancer: Ipilimumab is a human monoclonal antibody against the CTLA-4 antigen, and several studies have reported significant effects of combination of radiotherapy and Ipilimumab in the treatment of metastatic melanoma (108), non-small cell lung cancer (109) and prostate cancer (110).